withanolides and Leishmaniasis--Visceral

withanolides has been researched along with Leishmaniasis--Visceral* in 2 studies

Other Studies

2 other study(ies) available for withanolides and Leishmaniasis--Visceral

ArticleYear
Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in Leishmania donovani infected hamsters.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2017, Jan-15, Volume: 24

    Withania somnifera (L.) Dunal (Solanaceae), commonly known as Ashwagandha, is one of the most important medicinal plant in the traditional Indian medical systems. Pharmacological studies have established that root extracts of W. somnifera contain several bioactive constituents called withanolides. The plant has long been used for its several beneficial properties and recently as an immunomodulator.. A combination therapy including a potential and safe immunostimulant with lower doses of effective drug, which can reduce the parasitic burden and simultaneously can produce an enhancement of adaptive immunity, has proven to be significantly a more effective approach than immunotherapy or drug therapy alone.. Evaluation of the immunostimulatory effect of W. somnifera chemotype NMITLI 101R when used in combination with ED. The group of animals that received 101R and ED. Our results suggest that combination of chemotype 101R with ED

    Topics: Animals; Antiprotozoal Agents; Cricetinae; Leishmania donovani; Leishmaniasis, Visceral; Male; Mice; Mice, Inbred BALB C; Phytotherapy; Plant Extracts; Plants, Medicinal; Withania; Withanolides

2017
Efficacy of Withania somnifera chemotypes NMITLI - 101R, 118R and Withaferin A against experimental visceral leishmaniasis.
    Parasite immunology, 2014, Volume: 36, Issue:6

    The immunoprophylactic and therapeutic potentials of root extracts of Withania somnifera chemotypes (NMITLI-118, NMITLI-101) and pure withanolide-withaferin A was investigated against Leishmania donovani infection in hamsters. The naive animals, fed orally with immunostimulatory doses of chemotypes 101R, 118R (10 and 3 mg/kg) and withaferin A (9 and 3 mg/kg) for five consecutive days and challenged with Leishmania parasites on day 6, were euthanized on days 30 and 45 p.c. for the assessment of parasite clearance, real-time analysis of mRNAs of Th1/Th2 cytokines (IFN-γ, IL-12, TNF-α, iNOS/IL-4, IL-10 and TGF-β), NO production, reactive oxygen species (ROS) generation, lymphocyte transformation test and antibody responses. By day 45 p.c., there was a significant increase in the mRNA expression of iNOS, IFN-γ, IL-12 and TNF-α but decrease in IL-4, IL-10 and TGF-β, an enhanced Leishmania-specific LTT response as well as ROS, NO and antileishmanial IgG2 levels in 101R-treated hamsters followed by 118R- and withaferin A-treated ones, respectively. When these chemotypes were given to L. donovani-infected hamsters at different doses, there was moderate therapeutic efficacy of chemotype 101R (~50%) at 30 mg/kg × 5 followed by the other two. The results established that the 101R is the most potential chemotype and can be evaluated for combination therapy along with available antileishmanials.

    Topics: Animals; Antibody Formation; Cricetinae; Cytokines; Immunoglobulin G; Leishmania donovani; Leishmaniasis, Visceral; Male; Plant Extracts; Plant Roots; Th1 Cells; Withania; Withanolides

2014